TheStreet reports FDA barriers for patients on $1,500-a-month peptides
The piece centres on out-of-pocket peptide users and the regulatory status of the products they buy.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 10 16:37 ETSource: TheStreet
The wire
- 01TheStreet reports that patients paying as much as $1,500 a month for peptide therapy are running into an FDA problem.
- 02Cash-pay peptide demand sits largely outside approved-drug channels, so regulatory status directly affects what clinics and compounders can keep supplying.
- 03Only the headline framing is available here; readers should check the original for which peptides and which FDA action are at issue.
From the source
Read at thestreet.comPeptide patients paying up to $1,500 a month face an FDA problem
